JBI-802 (investigational oral agent for MPN/MDS-MPN with thrombocytosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-28 — Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis: Phase 1/2 first-in-human dose-escalation trial (3+3 design, starting 5 mg/day oral, 28-day cycles up to 2 years) launched in MPN and MDS/MPN with thrombocytosis (including ET), with planned expansion to other subtypes after RP2D determination. (novelty: 4)
Open questions
Related
Contributing findings
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
28-may-2026
novelty 4
per-area 4
introduces